Discontinued — last reported Q3 '23
Pfizer Interest Paid increased by 256.7% to $981.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 29.6%, from $1.39B to $981.00M. Over 4 years (FY 2021 to FY 2025), Interest Paid shows an upward trend with a 16.9% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
cf_interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $353.00M | $407.00M | $262.00M | $453.00M | $318.00M | $350.00M | $321.00M | $419.00M | $402.00M | $332.00M | $1.06B | $415.00M | $1.14B | $280.00M | $1.39B | $353.00M | $1.13B | $275.00M | $981.00M |
| QoQ Change | — | +15.3% | -35.6% | +72.9% | -29.8% | +10.1% | -8.3% | +30.5% | -4.1% | -17.4% | +219.9% | -60.9% | +174.2% | -75.4% | +397.9% | -74.7% | +220.1% | -75.7% | +256.7% |
| YoY Change | — | — | — | — | -9.9% | -14.0% | +22.5% | -7.5% | +26.4% | -5.1% | +230.8% | -1.0% | +183.1% | -15.7% | +31.3% | -14.9% | -0.7% | -1.8% | -29.6% |
We use cookies for analytics. See our Privacy and Cookie Policy.